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ttp://dx.doi.org/10.1016/j.ajpath.2014.04.013Myotonic dystrophy type 2 (DM2) is a multisystemic disorder caused by a (CCTG)n repeat expansion
in intron 1 of CNBP. Transcription of the repeats causes a toxic RNA gain of function involving
their accumulation in ribonuclear foci. This leads to sequestration of splicing factors and alters
pre-mRNA splicing in a range of downstream effector genes, which is thought to contribute to the
diverse DM2 clinical features. Hyperlipidemia is frequent in DM2 patients, but the treatment is
problematic because of an increased risk of statin-induced adverse reactions. Hypothesizing that
shared pathways lead to the increased risk, we compared the skeletal muscle expression proﬁles of
DM2 patients and controls with patients with hyperlipidemia on statin therapy. Neural precursor
cell expressed, developmentally downregulated-4 (NEDD4), an ubiquitin ligase, was one of the
dysregulated genes identiﬁed in DM2 patients and patients with statin-treated hyperlipidemia. In
DM2 muscle, NEDD4 mRNA was abnormally spliced, leading to aberrant NEDD4 proteins. NEDD4 was
down-regulated in persons taking statins, and simvastatin treatment of C2C12 cells suppressed
NEDD4 transcription. Phosphatase and tensin homologue (PTEN), an established NEDD4 target,
was increased and accumulated in highly atrophic DM2 muscle ﬁbers. PTEN ubiquitination was
reduced in DM2 myoﬁbers, suggesting that the NEDD4-PTEN pathway is dysregulated in DM2
skeletal muscle. Thus, this pathway may contribute to the increased risk of statin-adverse re-
actions in patients with DM2. (Am J Pathol 2014, 184: 2322e2332; http://dx.doi.org/10.1016/
j.ajpath.2014.04.013)Supported by Folkhälsan Research Foundation, University of Helsinki,
National Doctoral Program of Musculoskeletal Disorders and Biomaterials,
Liv och Hälsa Foundation, Vasa Central Hospital District Medical Research
funds Finnish Foundation of Cardiovascular Research (T.L.), Pirkanmaa
Hospital District grant 9N035 (T.L.), Tampere Tuberculosis Foundation
(T.L.), Emil Aaltonen Foundation (T.L.), NIH grant AR48171 (R.K.), a
Muscular Dystrophy Association grant (R.K.), and a Kleberg Foundation
grant (R.K.).
Disclosures: None declared.Myotonic dystrophy type 2 (DM2; Online Mendelian Inheri-
tance inMan 602668) is an autosomal dominantmultisystemic
disease with a highly variable phenotype, characterized by
adult- or late-onset proximal muscle weakness, myalgia,
myotonia, cardiac conduction defects, cataracts, insulin
resistance, mild cerebral involvement, and liver enzyme
elevation.1,2 DM2 is caused by an uninterrupted (CCTG)n
expansion of between 75 and 11,000 repeats in a polymorphic
(TG)n(TCTG)n(CCTG)n repeat tract in intron 1 of the CNBP
gene on chromosome 3q21.3,4 Typical features of DM2
muscle histopathology include extreme atrophy in a subpop-
ulation of type IIA ﬁbers, some of them as nuclear clump
ﬁbers, and an increased amount of internal nuclei.5 DM2 is astigative Pathology.
.common form ofmuscular dystrophy in adults, at least in some
European populations.6 The mutation frequency is as high as 1
in 1830 in the Finnish population,6 which suggests a clinical
manifestation frequency of 1 in 5000. On the basis of the late
NEDD4 Splicing in Myotonic Dystrophyonset of the symptoms, more than one-half ofmutation carriers
are asymptomatic at any given time.
In contrast to the more severe myotonic dystrophy type 1
(DM1), there is no congenital form of DM2, and the age of
onset and disease severity is not linked to the length of the
repeat expansion.7 DM2 pathogenesis has been shown to
result from an RNA gain-of-function pathomechanism that
involves sequestration of trans-acting nuclear proteins, such
as muscleblind-like 1, which co-localizes with mutant RNA
repeats in ribonuclear foci.8 This leads to missplicing of a
range of effector genes, including INSR,9 CLCN1,10 BIN1,11
CACNA1S,12 and other genes,13,14 which likely contribute
to the phenotypic features in patients with DM2. However,
other mechanisms, such as decreased CCHC-type zinc
ﬁnger, nucleic acid binding protein (CNBP) expression may
also have a role in the DM2 pathology.15
Patients who take statins have a dose-related and time-
dependent increased risk of adverse muscle reactions and
rhabdomyolysis.16 There is also a clear increase in the fre-
quency of adverse events during combination therapy or if
there is an underlying subclinical myopathy.17 Patients with
DM2 frequently have hyperlipidemia and often require
statin treatment.18,19 Among the patients diagnosed with
DM2 in Finland, a larger than average proportion had statin-
induced adverse muscle reactions, including the occasional
rhabdomyolysis.
Certain polymorphisms in SLCO1B120 have been associ-
ated with an increased risk of statin-induced myopathy.
Global expression proﬁling of skeletal muscles of patients
without myopathy on statin treatment has shown changes in
the calcium regulatory and the membrane repair machinery.21
In addition, changes in the cholesterol metabolism pathways
in muscle cell lines treated with statins have been reported.22
Our aim was to identify molecular factors that increase the
susceptibility of patients with DM2 to statin-adverse muscle
reactions by comparing the expression proﬁles in three
different muscle biopsy sets. Expression proﬁles of DM2
muscle biopsies were compared with previously published
DM2 muscle expression proﬁles13 and proﬁles of patients
with hyperlipidemia with no muscle disorders, taking sim-
vastatin.23 Our hypothesis was that similar molecular path-
ways would be affected in patients with DM2 and by statin
treatment. In this combined analysis we found 21 genes with
shared dysregulated expression. In addition, the prevalence
and relevance of the risk-associated polymorphism in
SLCO1B1 was analyzed in a large Finnish DM2 cohort.
Materials and Methods
Patient Material and Expression Studies
All patients with DM1 and with DM2 were from Finland
and were diagnosed by DNA mutation testing.4 Altogether
nine different DM2 patient samples were studied (clinical
information is summarized in Table 1). The main clinical
symptoms of the patients with DM2 consisted of muscleThe American Journal of Pathology - ajp.amjpathol.orgpain and stiffness, especially after exercise, and proximal
muscle weakness that was more pronounced in the lower
limbs. Only two patients had clinically detectable myotonia.
Half of the patients had hyperlipidemia, but none had dia-
betes mellitus. Whole genome expression array analysis was
performed on six DM2 and four control biopsies from the
vastus lateralis muscle with the use of the Illumina expres-
sion array platform (Illumina, Inc., San Diego, CA)
(Table 1). For the comparison, we included previously
published expression studies on DM2 patient biopsies13 and
simvastatin-treated hyperlipidemic persons.23 Biopsies of
the patients with DM2 A and B (Table 1) were used both in
the Illumina DM2 array study and in the previously reported
Affymetrix DM2 study.13 The study was approved by the
institutional review board of Tampere University Hospital,
and all patients gave written informed consent.
Microarray Expression Proﬁling
RNA Ampliﬁcation and Labeling
Muscle biopsies were homogenized with ultra-turrax (IKA
turrax, S8N-5 G), and total RNA was extracted with Trizol
(15596-018; Invitrogen, Carlsbad, CA) and puriﬁed with the
RNeasy kit (74106; Qiagen, Valencia, CA). The total RNA
was treated with DNase (79254; Qiagen) according to the
manufacturer’s recommendations. One hundred nanograms
of total RNA was ampliﬁed and biotinylated with the use of
the Illumina RNA Total Prep Ampliﬁcation kit (AMIL1791;
Ambion, Austin, TX) for 14 hours.
Gene Expression Analysis
The Illumina gene expression array analysis was performed at
the Microarray Center at Turku University by using 1.50 mg of
sample RNA with Sentrix Human-6 Expression BeadChips
version 2 (BD-25-113; Illumina, Inc.) at 58C overnight (17
hours) according to Illumina whole genome gene expression
with IntelliHybSeal-protocol, revisionB.Thehybridizationwas
detected with 1 mg/mL cyanine 3estreptavidine (PA43001; GE
Healthcare Bio-Sciences Corp., Piscataway, NJ). The expres-
sion arrays were scanned with Illumina BeadArray Reader and
analyzed with Bead Studio version 3.
The expression array raw intensity signals were analyzed
with Inforsense KDE version 2.0.4 (Inforsense, London, UK)
by using quantile normalization. This software was used for
single-gene analyses, including fold-change calculations and
ﬁltering of the probes. Statistical signiﬁcance was calculated
with an unpaired t-test. Probes that did not reach statistical
signiﬁcance (P  0.05) were removed from the data.
The microarray data are available from Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo; accession num-
ber GSE45331).
Pathway Analysis
Pathway changes were identiﬁed with the Database for
Annotation, Visualization and Integrated Discovery ontology2323
Table 1 Patient and Control Biopsies Used in Illumina Gene Expression Analysis, RT-PCR, and Western Blot Analysis
Name
Sex/age
at biopsy
(years) Method Muscle symptoms Clinical ﬁndings
Hyper-
lipidemia Diabetes
Myotonic dystrophy type 2
Patient A M/49 EA Exercise-induced myalgia Normal muscle strength, calf
hypertrophy
Yes No
Patient B M/38 EA Exercise-induced myalgia and
weakness
Clinical myotonia, mild proximal
lower limb atrophy
Yes No
Patient C (*1) F/34 EA Muscle stiffness, clumsiness Normal muscle strength, myotonia
on EMG
No No
Patient D (*2) F/41 EA Difficulties in climbing stairs,
muscle stiffness
Proximal lower limb weakness,
clinical myotonia
No No
Patient E (*3) M/55 EA Exercise-induced myalgia,
muscle stiffness
Proximal weakness and atrophy, calf
hypertrophy, myotonia on EMG
No No
Patient F (*4) M/37 EA Muscle stiffness Mild proximal weakness, myotonia
on EMG
Yes Insulin
resistance
DM2-A (*5) M/44 PCR Exercise-induced myalgia and
weakness, muscle stiffness
Mild proximal weakness NA No
DM2-B (*4) M/37 PCR See patient F
DM2-C F/63 PCR Mild bent spine syndrome Axial and proximal weakness Yes No
DM2-D M/51 PCR Difficulties in climbing stairs,
muscle stiffness
Proximal weakness, myotonia on
EMG
NA No
D1 (*3) M/55 WB See patient E
D2 (*1) F/34 WB See patient C
D3 (*2) F/41 WB See patient D
D4 (*5) M/44 WB See DM2-A
Controls
Ctrl A M/52 EA
Ctrl B M/45 EA
Ctrl C M/50 EA
Ctrl D M/54 EA
C-1 M/79 PCR
C-2 M/80 PCR
C-3 F/U PCR
C1 U/>65 WB
C2 U/>65 WB
Myotonic dystrophy type 1
DM1-A M/34 PCR
DM1-B F/42 PCR
DM1-C M/50 PCR
DM1-D F/47 PCR
*Overlapping biopsies indicating the same patient’s biopsy was present in different experiments.
F, female; M, male; Ctrl, control; DM1, myotonic dystrophy type 1, DM2, myotonic dystrophy type 2; EA, expression array; EMG, electromyography; NA, not
available; U, unknown; WB, Western blot analysis.
Screen et aldatabase (http://david.abcc.ncifcrf.gov, last accessed January
24, 2011) with KEGG (Kyoto Encyclopedia of Genes and
Genomes) downstream annotations. Signiﬁcant pathway
enrichment in the DM2 expression data were calculated with
EASE score (modiﬁed Fisher exact t-test) with multiple
testing correction (BenjaminieHochberg). The pathways
were ranked with the EASE score t-test (P  0.05).
SLCOB1 Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes by using the QIAamp DNA Blood Mini-kit.
The SLCO1B1 single nucleotide polymorphism (SNP)2324rs4149056 was genotyped with TaqMan genotyping assays
(Applied Biosystems, Foster City, CA). Random duplicates
were used as controls.
RT-PCR and Quantitative Real-Time PCR
cDNA was generated with 1 mg of total RNA from myotube
cultures or from muscle tissue by using the Trizol reagent
(Invitrogen) according to the manufacturer’s instructions.
In vitro transcription was performed with random hexamers
and oligo-(dT) priming according to the manufacturer’s
instructions (SuperScript III First-strand cDNA Synthesis
Kit; Invitrogen). The PCR products were ampliﬁed withajp.amjpathol.org - The American Journal of Pathology
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ON, Canada) and were separated on an agarose gel. PCR
products were identiﬁed by sequencing of representative
DNA bands. Primer sequences are given in Table 2.
Quantiﬁcation of the cDNA was performed with
TaqMan-based quantitative real-time PCR by using NEDD4
(Hs00406454_m1), Gapdh (Mm99999915_g1), and GAPDH
(4333764F) primers and probes (Life Technologies, Carls-
bad, CA). TaqMan master mix (10 mL; Applied Bio-
systems), 0.5 mL of 1:10 diluted cDNA, and 2 mL of primer
and probe sets were used in a 20-mL total reaction volume.
Ampliﬁcation and detection were performed with the ABI
7500 system (Applied Biosystems). The PCR thermal con-
ditions were 50C for 2 minutes, 95C for 10 seconds, and
60C for 1 minute. Each sample was performed in triplicate
and normalized to GAPDH by using standard curves for
each gene on the same plate.
Western Blot Analysis
Muscle biopsies were prepared for SDS-PAGE by homog-
enization with 19 volumes of sample buffer that contained 4
mol/L urea and 4% SDS at 100C for 5 minutes. Samples
were resolved with 12% SDS-PAGE gels with 4% stacking
gels and transferred to polyvinylidene diﬂuoride membranes
(Bio-Rad Laboratories, Hercules, CA) according to the
manufacturer’s instructions.
Antibodies
Antibodies used in immunoblotting, immunoﬂuorescence
(IF), and immunohistochemistry (IHC) are rabbit mono-
clonal antiephosphatase and tensin homologue (PTEN; IF
and IHC dilution 1:100; 6H2.1; Millipore, Billerica, MA),
rabbit polyclonal anti-ubiquitin (dilution 1:150; Z0458; Dako
UK Ltd., Ely, UK), mouse anti-dystrophin (dilution 1:50;
Dy4/6D3; Novocastra, Newcastle, UK), polyclonal rabbit
anti-NEDD4 (dilution 1:1000; NBP1-03462; Novus Bi-
ologicals, Inc., Littleton, CO), mouse anti-GAPDH (dilution
1:20,000; ab8245; Abcam, Cambridge, MA), and rabbit
monoclonal anti-MBNL1 (dilution 1:1000; ab108519;
Abcam). Primary antibodies were detected with secondaryTable 2 A List of Primers Used in RT-PCR Analysis
Oligonucleotide Sequence
NEDD4 006-1L 50-CTCCTCCTCCTCCACAGTTG-30
NEDD4 006-1R 50-CGGTGCTGCTGAGGATGA-30
NEDD4 Fwd: 50-TTGCAGCAACAACAAGAACC-30
Rev: 50-GCAAGTCCAGGCGATTAAAA-30
Nedd4 Fwd: 50-CACAGTGGAAAAGGCCAAGC-30
Rev: 50-ACCTGGTGGCAATCCAGATG-30
GAPDH Fwd: 50-TTAGCACCCCTGGCCAAGG-30
Rev: 50-CTTACTCCTTGGAGGCCATG-30
Fwd, forward; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
NEDD4, neural precursor cell expressed, developmentally down-regulated 4,
E3 ubiquitin protein ligase; Rev, reverse.
The American Journal of Pathology - ajp.amjpathol.orghorseradish peroxidaseeconjugated antibodies (dilution
1:100; DAKO P260; DakoCytomation, Glostrup, Denmark)
and enhanced chemiluminescence with the Immun-Star kit
(Bio-Rad Laboratories). Secondary horseradish perox-
idaseeconjugated antibodies were diluted at 1:1000 in
Western blot analysis.
Cell Culture and IP
Cell culture of biopsies was performed as described previ-
ously.15 Immunoprecipitation (IP) assays of PTEN were
done according to the manufacturer’s instructions (Pierce
cross-linking IP kit; Thermo Fisher Scientiﬁc, Inc., Wal-
tham, MA). PTEN was captured with the anti-PTEN anti-
body (dilution 1:100; ab32199; Abcam) and identiﬁed by
Western blot analysis as described above.
IHC and IF
DM2 muscle biopsies (n Z 6) and control muscle biopsies
(nZ 2) were snap frozen in liquid nitrogen-cooled isopentane
for 6 mm cryosections on SuperFrost. IHC staining was per-
formed with the NovoLink Min Polymer detection system
(reference RE7290-K; Leica Microsystems, Milton Keynes,
UK) by using the aforementioned antibodies. IF was per-
formed as previously described15 by using Alexa Fluor 680
donkey anti-mouse (A10038; Invitrogen) and Alexa Fluor 405
goat anti-rabbit (A31556; Invitrogen) secondary antibodies
(dilution 1:1000). Fluorescencewas detectedwith anAxioplan
Imager 2 microscope (Carl Zeiss MicroImaging GmbH, Jena,
Germany) with a high-resolution, cooled camera. AxioVision
version 4.6 (Carl Zeiss) was used for image acquisition.
Cell Culture and Simvastatin Treatment
Simvastatin (S6196; Sigma-Aldrich, St. Louis, MO) was
converted into the active acid according to the manufacturer’s
instructions. C2C12 myoblasts were grown in Dulbecco’s
modiﬁed Eagle’s medium (Gibco 41965; Invitrogen) with
high glucose (4.5 g/L) and supplemented with 10% fetal
bovine serum, 50 U/mL penicillin, and 50 mg/mL strepto-
mycin. Myoblasts were seeded in T25 ﬂasks for 2 days until
fully conﬂuent and differentiated in Dulbecco’s modiﬁed
Eagle’s medium with high glucose that was supplemented
with penicillin, streptomycin, and 2% horse serum. After 1
week simvastatin-containing media were added to the myo-
tubes (no treatment, ethanol vehicle, 1 mmol/L, and 10
mmol/L) in quadruplicate. The cells were harvested after 6
hours, and RNA was extracted with an RNeasy kit (Qiagen).
cDNA was then produced, and PCR products were ampliﬁed
with mouse primers. Cells were also harvested after 2 days of
simvastatin treatment, and total protein was extracted for
Western blot analysis. Band intensities were quantiﬁed with
ImageJ version 1.46f (NIH, Bethesda, MD). Signiﬁcance of
changes between treatment groups was calculated with a two-
tailed equal variance t-test.2325
Table 3 The Frequency of the rs4149056 SNP Allele in Finnish Patients with DM2
Genotype T/T [% (n)] C/T [% (n)] C/C [% (n)]
Finnish population 63.9 31.8 4.3
Patients with DM2 (n Z 126) 57.1 (72) 38.9 (49) 4.0 (5)
Patients with DM2 with statin complications (n Z 6) 33 (2) 66 (4) 0
The normal Finnish population frequency has been previously published.1 The SLCO1B1 c.521 TC and c.521 CC genotypes are associated with a signiﬁcantly
increased risk of statin-induced myopathy compared with the c.521 TT genotype. The c.521 CC genotype confers the highest risk of adverse reactions.
DM2, myotonic dystrophy type 2; SNP, single nucleotide polymorphism.
Screen et alPlasmids for shRNA expression that target all protein-coding
isoforms of MBNL1 and a scramble control were purchased
from GeneCopoeia (Rockville, MD). Two combined shRNAs
were used that contained the target sequence n7 (50-CAAT-
TGCAACCGAGGAGAA-30) or n8 (50-AGATCAAGGCT-
GCCCAATA-30) in theHSH011081-7-mU6 vector. HEK293T
cells were plated on 6-well plates at 150,000 cells per well and
transfectedwith 2 mg of combinedMBNL1 shRNAplasmids or
a scramble control (CSHC TR001-mU6) by using FuGene 6
(Promega, Madison, WI) and OptiMem (Life Technologies)
according to the manufacturer’s instructions. Cells were har-
vested 72 hours after transfection for Western blot analysis and
RNA extraction.Results
Clinical Observation of Incidence
Eight patients referred to the Neuromuscular Research Center
(Tampere University and University Hospital, Finland)
because of simvastatin-induced muscle symptoms (muscle
pain/weakness and elevated levels of creatine kinase,
including one case of rhabdomyolysis) proved to have DM2
on genetic examination. In the same 2004 to 2007 period, a
total of 89 patients were diagnosed with DM2. Twelve of
these patients were diagnosed in family studies, 77 wereTable 4 Summary of the DAVID Ontology Analysis
KEGG pathway term Percent (%)*
hsa04120: Ubiquitin-mediated proteolysis 1.13
hsa04510: Focal adhesion 1.51
hsa04310: Wnt signaling pathway 1.16
hsa04210: Apoptosis 0.74
hsa05200: Pathways in cancer 2.17
hsa05016: Huntington’s disease 1.28
hsa04010: MAPK signaling pathway 1.78
hsa04722: Neurotrophin signaling pathway 0.93
hsa04520: Adherens junction 0.62
hsa03018: RNA degradation 0.49
hsa05210: Colorectal cancer 0.66
hsa05010: Alzheimer disease 1.13
hsa04144: Endocytosis 1.25
DAVID ontology analysis with KEGG pathway indicates signiﬁcantly dysregulate
EASE score of gene enrichment analysis. Multiple testing corrections were applie
threshold of two genes for a given term was used.
*Number of genes involved in a term/total genes of the pathway.
BH, BenjaminieHochberg; DAVID, Database for Annotation, Visualization and
KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated prot
2326primary referrals of undetermined muscle disease, and
among them were the eight patients with simvastatin-adverse
reactions. Thus, 10% of the primary referred patients who
proved to have DM2 had simvastatin-induced symptoms as
the main cause of referral. During the 2008 to 2009 period, 19
further patients were referred for neuromuscular evaluation
because of statin-induced muscle symptoms, of which 4 pa-
tients (21%) had a subsequent genetic diagnosis of DM2.
Risk-Associated SLCO1B1 SNP Frequency in Patients
with DM2
Genotyping of the known myopathy-associated SNP
rs4149056 in SLCO1B120 was performed in six of the eight
patients with DM2 referred for primary statin-induced mus-
cle reactions, including one patient with rhabdomyolysis. In
addition, a second larger cohort of 126 patients with DM2
was also included. No correlation was found between theC/C
genotype and statin susceptibility in patients with DM2, at
least for the highest risk of adverse reaction (Table 3).
Microarray Gene Expression Proﬁling
Shared expression changes were identiﬁed in the expression
proﬁles of DM2 muscle biopsies and in persons who were on
statin medication because of hyperlipidemia. The expressionFold enrichment EASE P value BH P value
1.65 0.000003 0.0006
1.51 0.000005 0.0005
1.54 0.000036 0.0023
1.70 0.000073 0.0036
1.33 0.000109 0.0043
1.42 0.000319 0.0104
1.34 0.000327 0.0092
1.49 0.000618 0.0151
1.62 0.001053 0.0228
1.71 0.001464 0.0284
1.56 0.001662 0.0293
1.39 0.001750 0.0283
1.36 0.001970 0.0294
d pathways in DM2 muscles expression proﬁle versus controls by using an
d to the EASE score, and a threshold (P  0.05) was applied. A minimum
Integrated Discovery; EASE score, modiﬁed one-tailed Fisher exact t-test;
ein kinase.
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Figure 1 A:Quantitative PCRanalysis ofNEDD4expression inDM2, control,
and DM1 muscle cDNAs. The primers annealed to a region present in all of the
protein coding NEDD4 isoforms (001 to 006; Ensembl).B: TheNEDD4 forward
reverse primers set bind and amplify the native full-length NEDD4 isoforms
(2033-bp bands) and another novel NEDD4 splicing form (274-bp band) that
was conﬁrmed by sequencing. GAPDH shows similar levels of expression be-
tween samples. RT-PCR analysis of the NEDD4-006 (ENST00000435532) tran-
script in DM2, control, and DM1muscle biopsies. TheNEDD4 006-1L and 006-1R
primer set bind and amplify the native NEDD4-006 transcript (327 bp) and a
novel (207 bp) extra band. The bandwas conﬁrmed by sequencing to be a novel
splice isoform that was missing all of exon 3 and 4, leading to a change in
reading frame, 18 new amino acids, and a premature stop codon. C: The short
isoform-speciﬁc splice site locations in the NEDD4-002 (ENST00000508342)
transcript in B. Expressed sequence is in bold. Data are expressed as means
SEM. *P  0.05, **P  0.01, t-test. WT, wild type.
NEDD4 Splicing in Myotonic Dystrophyarray analysis of DM2 muscle biopsies by using the Illumina
platform did not provide identical signiﬁcant differences for
some of the genes that were reported in our previous
Affymetrix-basedmicroarray study.13Thedifferences observed
between the twoplatformsmaybe due to thedifferent probe sets
recognizing different transcript isoforms. Because of these
differences, someof the expression proﬁle leadswereveriﬁed in
DM2 muscle samples by RT-PCR, with the aim of identifying
aberrantly spliced genes. There were 33 genes that were
abnormally expressed in both theDM2expression proﬁling and
in expression proﬁling of persons taking statins compared with
controls (Supplemental Table S1). Of the 33 genes identiﬁed,
four (BIRC3, NEDD4, UBE2D1, and USP6) belonged to the
ubiquitin proteasome pathway.
Pathway Analysis
Pathway analysis indicated that the ubiquitin-mediated
proteolysis pathway was the most severely affected, both
ranked by signiﬁcance and by representation in the DM2
expression array pathway analysis (Table 4).
NEDD4 Analysis
The DM2 muscle expression analysis indicated an increase in
ubiquitin ligase NEDD4mRNA at the probe level (Affymetrix
213012_at; fold change, 1.72; P Z 0.00007). This increase
was also found by quantitative real-time PCR analysis of the
main NEDD4 isoform in DM2 muscles (Figure 1A). The total
protein level of NEDD4 did not appear to change in IHC (data
not shown) or by Western blot analysis (Figure 2). However,
two previously unreported splice isoforms of NEDD4 were
identiﬁed by RT-PCR analysis. A smaller isoform of NEDD4
was shown to be present in DM2 and DM1 biopsies but not in
controls (Figure 1B). The total level of cDNA in samples was
measured by GAPDH levels (Figure 1B). This splice isoform
was found to be in frame but lacking 16 full exons and parts of
exons 5 and 22 (002, ENST00000508342) (Figure 1C). By
Western blot analysis, a NEDD4-positive band of approxi-
mately 75 kDa was identiﬁed only in the DM2 samples
(Figure 2), which could result from alternative splicing of
transcripts NEDD4-002 (ENST00000508342) orNEDD4-003
(ENST00000506154) with a theoretical size of 80 kDa and 78
kDa, respectively. In addition, a second novel short isoform
was present in DM2 biopsies but not in controls or DM1 bi-
opsies (Figure 1B). This isoformwas missing all of exon 3 and
4 of the NEDD4-006 (ENST00000435532) transcript, causing
a frameshift that lead to 18 new amino acids and a premature
stop codon (all accessed from Ensemble, http://www.ensembl.
org/index.html). The level of the full-length NEDD4-006 iso-
form in DM2 biopsies was decreased compared with controls
(Figure 1B).
MBNL1 Silencing
To further validate the abnormal expression of the two novel
isoforms of NEDD4 we knocked down MBNL1 with theThe American Journal of Pathology - ajp.amjpathol.org 2327
Figure 2 Western blot of DM2 (DM2, 1 to 4) and control (C1 to C2)
muscle biopsy extracts stained with NEDD4 and PTEN antibodies. WT NEDD4
isoforms are predicted from Ensembl to be 149, 147, 141, 105, and 104 kDa
in size. A DM2-speciﬁc NEDD4 band (approximately 75 kDa) corresponding
to the aberrant DM2 transcript was present in all four patient biopsies.
Protein loading is shown by the myosin band in Coomassie Blue staining.
WT, wild-type.
Screen et aluse of shRNAs in HEK293T cell cultures. Silencing of
MBNL1 (Figure 3A) led to a signiﬁcant increase in the level
of the novel NEDD4-006 isoform missing exon 3 and 4
compared with the scramble controls (Figure 3B). The small
NEDD4 isoform missing 16 full exons (Figure 1B) was not
signiﬁcantly different from the controls after MBNL1
silencing (not shown).
PTEN Analysis
To check for possible downstream effects of NEDD4 ab-
normality in DM2 muscle, we studied the NEDD4 ligand
PTEN. The original DM2 muscle expression analysis indi-
cated an increase in PTEN mRNA levels (Affymetrix
225363_at; fold change, 1.5; PZ 0.01). IF staining of DM2
biopsies showed clear accumulation of PTEN in the highly
atrophic type IIA ﬁbers (Figure 4, AeD), including the nu-
clear clump ﬁbers. IHC conﬁrmed that the increased PTEN
signal was not due to multichannel-ﬂuorescent lipofuscin
(Figure 4, E and F). The total PTEN level showed a trend
toward being increased in DM2 myotube cultures compared
with controls in Western blot analysis (Figure 5A), but it did
not reach signiﬁcance.2328PTEN Ubiquitination
We performed IP of PTEN from DM2 patient and control
myotube culture extracts. The level of ubiquitinated PTEN
was decreased in the DM2 pull-downs compared with the
control samples when total PTENwas normalized (Figure 5B).
Simvastatin Treatment of Skeletal Muscle Cells
The expression proﬁling of hyperlipidemic persons on statin
medication showed a decrease in the NEDD4 transcript at
the probe level (Illumina 3060017; fold change, 1.59;
P Z 0.03). C2C12 myotube cultures showed a signiﬁcant
dose-dependent reduction of NEDD4 mRNA expression
compared with the vehicle controls after 6 hours of simvastatin
treatment (Figure 6A). After 2 days of simvastatin treatment,
C2C12 myotube cultures showed a signiﬁcant dose-dependent
increase in the PTEN protein levels compared with vehicle
controls (Figure 6B). Decreased NEDD4 levels have been
shown to cause decreased PTEN ubiquitination and thereby
increase PTEN levels.24 We therefore performed IP of PTEN
from the C2C12 cell extracts to enable measurements of its
ubiquitination. Once total PTEN was normalized, the
simvastatin-treated cells showed reduced ubiquitination of
PTEN compared with untreated cells (Figure 6C).
Discussion
Patients with DM2 are frequently diagnosed with hyper-
lipidemia, and many are therefore prescribed statin medi-
cation. The observed increase of statin-adverse muscle
reactions that cause medical attention among patients with
DM2 did, however, not appear to be linked to the co-
segregation of the reported statin-adverse reaction risk C-
allele of SNP rs414905620 in Finnish patients with DM2.
Therefore, some other molecular factor(s) apparently un-
derlie the increased susceptibility of statin-provoked muscleFigure 3 HEK293T cell cultures were trans-
fected with two combined vectors that express
shRNA against a region of MBNL1 that is present in
all protein coding isoforms (M1 to M4) or a
scramble control (S1 to S4). A: Western blot
analysis of MBNL1 shRNAe and scramble shRNAe
treated protein extracts, normalized to GAPDH,
shows an 80% decrease in MBNL1 protein levels.
cDNA was produced from RNA extracted from the
same transfected HEK293T cell cultures and
ampliﬁed with the NEDD4 006-1L and 006-1R
primer set. B: MBNL1 shRNAetransfected cell
culture shows a signiﬁcant increase in the level of
the novel NEDD4-006 splice isoform (missing exon
3 and 4 are shown in the box) after normalization
to GAPDH. Data are expressed as means  SEM.
*P  0.05, t-test.
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Figure 4 IF staining for PTEN (red), dystrophin (green), and DAPI (blue) in three different DM2 muscle biopsies (AeC) and a control (D). IHC of PTEN and
hematoxylin counterstain in a patient with DM2 (E) and a control (F). Both techniques show accumulation of PTEN in nuclear clump ﬁbers and highly atrophic
ﬁbers in DM2 samples. Scale bars: 50 mm (AeF).
NEDD4 Splicing in Myotonic Dystrophyreactions in patients with DM2. Statin-induced myopathy in
the general population has been proposed to have an
immune-mediated mechanism.25 However, all our patients
with DM2 with statin-adverse reactions underwent muscle
biopsy, and no evidence of immune reactivity was identiﬁed
by major histocompatibility class 1 IHC (not shown).
By expression proﬁling analysis, we found dysregulation
in ubiquitination pathway components in the DM2 biopsies.
Increases in expression of components in the ubiquitin-The American Journal of Pathology - ajp.amjpathol.orgproteasome pathway have previously been described in
muscle of persons who are exercising and taking statins26
and in persons with statin-induced adverse reactions.27
The up-regulation of genes involved in the ubiquitin-
proteasome pathway have been suggested to be a response
to myoﬁbrillar damage,28 inducing ubiquitination of pro-
teins targeted for proteasome degradation.
The expression proﬁling of persons treated with statins,
but with no muscle disorders, indicated that statin treatment2329
Figure 5 PTEN IP assay from DM2 and control
myotube culture extracts. A: Background IP levels
are shown by the () lanes. The (þ) lanes indicate
the presence of the primary antibody. Total protein
levels were measured from b-actin immunostaining
of myotube protein extracts, and the same amount
of IP extract was then PTEN stained. B: PTEN levels
were determined by staining of IP extracts, and
the same amount of PTEN IP extract was then
ubiquitin stained. Data are expressed as means 
SEM. *P  0.05, t-test. Ctrl, control.
Screen et alrepresses transcription of NEDD4 in human muscle tissue.
Here, we conﬁrm that simvastatin treatment causes repres-
sion of NEDD4 transcription in mouse myotube cultures.
Because NEDD4 is a negative regulator of PTEN,24,29 this
result is in agreement with our results showing that simva-
statin increases PTEN protein levels in C2C12 myotubes.
NEDD4 is an E3 ubiquitin-protein ligase that transfers
ubiquitin from an E2 ubiquitin-conjugating enzyme to target
substrates. Ubiquitinated substrates are then transferred to
the proteasome for degradation.30 Alterations in theFigure 6 C2C12 myotube cultures were treated with simvastatin (no treatme
expression was determined by quantitative real-time PCR. B: C2C12 myotube cultu
immunoblotting. C: PTEN IP assay was performed on the same C2C12 myotube pr
levels and ubiquitin immunoblotted. PTEN, ubiquitin, and b-actin protein levels we
Data are expressed as means  SD according to four replicates (A) or as means  S
blot analyses.
2330expression of NEDD4 may therefore directly affect the
cellular level of its substrates, such as PTEN.24,29 The
importance of NEDD4 in muscle is supported by Nedd4þ/
knockout mice, which have muscle weakness and histo-
logically show a marked reduction in skeletal muscle ﬁber
size and increased amount of internal nuclei.31
Our results indicate that the expression of NEDD4 is
increased and abnormally spliced in DM2 muscle tissue.
The increased level of NEDD4 mRNA in DM2 muscles
may be due to its role in the ubiquitin/proteasome pathwaynt, vehicle, 1 mmol/L, and 10 mmol/L) for 6 hours. A: The NEDD4/GAPDH
res were treated for 2 days and analyzed by Western blot analysis and PTEN
otein extracts. The C2C12 myotube extracts were normalized by total PTEN
re determined by Western blot analysis and quantiﬁed with ImageJ analysis.
EM (B and C). **P  0.01, t-test for both the quantitative PCR and Western
ajp.amjpathol.org - The American Journal of Pathology
NEDD4 Splicing in Myotonic Dystrophyresponse to myoﬁbrillar damage. A novel splice isoform that
is missing exon 3 and 4 from the NEDD4-006 transcript was
present in DM2 muscle but not in controls or DM1 muscle.
The loss of the exons causes a frameshift, leading to 18 new
amino acids and a premature stop codon. Even though there
was an overall NEDD4 increase in DM2 samples
(Figure 1A), we observed a reduced amount of the NEDD4-
006 isoform in DM2 samples compared with controls.
These changes may affect the ability of NEDD4 to function
in the ubiquitin-proteasome pathway. The MBNL1 protein
has been previously linked to both the DM2 pathology and
the DM2 splicing changes.7 Silencing MBNL1 in cell cul-
ture causes the mRNA level of the new 006 isoform to be
increased. This suggests MBNL1 regulates NEDD4 splicing
in muscle and that it may have a role in the DM2 pathology.
Silencing MBNL1 did not affect the mRNA level of the
other short NEDD4 splice isoform (Figure 1B). This sug-
gests that other molecules are important for the ﬁnal regu-
lation of NEDD4 splicing and that these unknown factors
are also affected by the DM2 mutation. In Western blot
analysis a band that was consistent with the smaller NEDD4
splice isoform (missing 16 full exons) was observed in DM2
samples alongside bands that corresponded to full-length
NEDD4 isoforms. The missing region encodes critical do-
mains, such as large parts of the HECT (homologous to the
E6AP carboxyl terminus) and WW1 domains, and all of the
WW2 to WW4 domains, while still containing the C2
domain. This most likely causes loss of function in the
DM2-speciﬁc abnormal splice isoform, while still main-
taining some of the binding interactions. Although the
abnormal isoform is not predominant, on the basis of the
amount on Western blots, a dominant negative effect cannot
be excluded. Interestingly, the in vivo expression of inacti-
vated Nedd4 in mouse skeletal muscle causes a dominant
negative effect.32
NEDD4 has been shown to be an important regulator of
PTEN turnover. Disruption of NEDD4 in muscle tissue
reduces the ubiquitination of PTEN, thus increasing its
protein level through a decrease of its degradation turnover.
Our results indicate a decrease in the level of PTEN ubiq-
uitination in DM2 myotube cultures compared with con-
trols. PTEN accumulates in a subpopulation of highly
atrophic IIA ﬁbers, including the typical nuclear clump IIA
ﬁbers in DM2 muscle. Together, our ﬁndings suggest de-
fects in NEDD4 activity in DM2. Statin medication reduces
the overall level of NEDD4 expression, which in turn in-
creases the level of PTEN and reduces PTEN ubiquitination.
The identiﬁed NEDD4 dysregulation, including the abnor-
mally spliced NEDD4 isoforms in DM2, could therefore
increase susceptibility for the adverse reactions of statin by
reducing the level of functionally active NEDD4 even
further. This could explain why previously subclinical pa-
tients with DM2 more frequently present ﬁrst symptoms
when they are on statin medication and would favor
hyperlipidemia therapies that do not have negative effects
on the NEDD4 pathway.The American Journal of Pathology - ajp.amjpathol.orgAcknowledgments
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